Literature DB >> 24035406

Immunological checkpoint inhibitors enter adolescence.

Anna K Nowak1.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24035406     DOI： 10.1016/S1470-2045(13)70401-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  7 in total

Review 1.  Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors.

Authors:  Ning Zhu; Shanshan Weng; Juan Wang; Jiaqi Chen; Linzhen Yu; Xuefeng Fang; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2019-10-15       Impact factor: 4.553

2.  Novel immune checkpoint blocker approved for the treatment of advanced melanoma.

Authors:  Lorenzo Galluzzi; Guido Kroemer; Alexander Eggermont
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 3.  Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Aurélien Marabelle; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

Review 4.  Trial Watch: Peptide-based anticancer vaccines.

Authors:  Jonathan Pol; Norma Bloy; Aitziber Buqué; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

5.  The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.

Authors:  Andrea Khong; Amanda L Cleaver; Muhammad Fahmi Alatas; Ben C Wylie; Theresa Connor; Scott A Fisher; Steve Broomfield; Willem J Lesterhuis; Andrew J Currie; Richard A Lake; Bruce W Robinson
Journal:  BMC Cancer       Date:  2014-12-17       Impact factor: 4.430

Review 6.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

7.  Impact of serum soluble CD155 level at diagnosis on interim response to CHOP with or without rituximab in diffuse large B cell lymphoma.

Authors:  Mohamed Osman Azzazi; Hany Mohamed Hegab; Amro Mohamed Sedky El-Ghammaz; Heba Mohamed Saber; Youssef Adel Afifi
Journal:  Clin Exp Med       Date:  2021-07-03       Impact factor: 3.984
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.